SENSEX NIFTY
Ranbaxy Laboratories > Company History > Pharmaceuticals > Company History of Ranbaxy Laboratories - BSE: 500359, NSE: RANBAXY
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > COMPANY BACKGROUND - Ranbaxy Laboratories
Ranbaxy Laboratories
BSE: 500359|NSE: RANBAXY|ISIN: INE015A01028|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Aug 28, 10:55
645.10
-3.65 (-0.56%)
VOLUME 21,821
LIVE
NSE
Aug 28, 10:55
644.65
-3.95 (-0.61%)
VOLUME 165,934
Company History - Ranbaxy Laboratories
1961
 
 - The Company was Incorporated on 16th June, 1961 at Delhi.  The
 Company Manufacture drugs, medicines, cosmetics and chemical
 products. The company also markets a wide range of products including
 a number of life saving antibiotics.
 
 1973
 
 - The shareholders of the Company offered for sale to the public
 during October simultaneously with the public issue of shares 63,535
 equity shares of Rs 10 each of the Company at par.
 
 1977
 
 - The Company had set up a joint venture company with local
 participation in Nigeria.  The equipments to be supplied against the
 Companmy's contribution to the equity capital were ordered.  These
 were shipped during 1978 and were received and installed in Nigeria.
 Production commenced in early 1980.
 
 1984
 
 - Ranbaxy Investments Ltd., Medicare Investments Ltd., and Cheminvest
 Ltd., became subsidiaries of the Company.
 
 1985
 
 - Approval of the Malaysian Government was received for a joint
 venture project.  The project commenced production in July 1987.
 
 - In October the Company made a rights issue of 1,00,000 equity
 shares of Rs 10 each linked to 15,00,000-15% secured redeemable
 non-convertible debentures of Rs 100 each, both at par on the
 following basis:
 
 - (i) 9,09,000 equity shares tied to 13,63,500-15% debentures to the
 existing equity shareholders and holders of the convertible parts of
 13.5% secured debentures in the ratio 27 debentures and 18 equity
 shares for every 50 equity shares or 10 convertible parts of the
 13.5% debentures held,
 
 - (ii) 71,000 equity shares tied to 1,06,500 debentures as
 preferential allotment to equitable basis to employees, and 
 
 - (iii) 20,000 equity shares tied to 30,000 debentures to business
 associates.  The issue was oversubscribed and the Company allotted a
 further 2,50,000 equity shares tied to 3,75,000 bedentures to retain
 oversubscription.
 
 - Ranbaxy Drugs Ltd., became a subsidiary of the Company.  Montari
 Agro Chem Investment Ltd., Montari Chemicare Investments Ltd., Chahel
 Investment & Trading Co., Ranpharm Investment Ltd., Raicure Investment
 Ltd., & Vidyut Inv. are subsidiaries of the Company.
 
 1986
 
 - 9.8% Pref. shares redeemed.  39,510 equity shares issued in
 conversion of 13.5% debentures.
 
 1987
 
 - An antibiotic plant at Toansa, Dist. Hoshiarpur (Punjab) and the
 Nalidixic Acid plant as SAS Nagar (Punjab) were commissioned.
 
 - 7,000-11% Pref. shares redeemed.  45,680 equity shares issued in
 conversion of 13.5% debentures. (Final conversion).
 
 1988
 
 - A new broad spectrum oral fluoroquinolone of loxacin under the
 brand name Zanocin was launched in the market in April 1990.
 
 - The Company offered 16,64,775-12.5% secured fully convertible
 debentures of Rs 100 each for cash at par aggregating to Rs
 16,64,77,500.  Of these, 15,85,500 debentures were offered to the
 shareholders on rights basis in the proportion 30 debentures: 100
 equity shares (all were taken up).  The balance 79,275 debentures
 were offered to the employees (including Indian working Directors)
 (all were taken up).  Additional 2,49,716 debentures were allotted to
 retain 
 oversubscription (2,37,825 debentures to the shareholders and 11,891
 debentures to the employees).
 
 - Each debenture was converted into 2 equity shares of Rs 10 each at
 a premium of Rs 40 per share on 31.3.1989.  Accordingly, 38,28,982
 equity shares of Rs 10 each were issued.  Subject to necessary
 approvals being obtained, the Company proposed to issue
 13,67,097-12.5% secured redeemable partly convertible debentures of
 Rs 300 each on rights basis to the existing equity shareholders in
 the ratio of 9 debentures for every 100 equity shares held. 
 Simultaneously, the Company proposed to offer, 68,355 debentures to
 the employees/workers of the Company.
 
 - As per the proposed terms of issue, part-A of Rs 200 of each
 debenture will be converted into four equity shares of Rs 10 each at
 a premium of Rs 40 per share at the end of 6 months from the date of
 allotment.  The non-convertible part-B of each debenture will be
 redeemed at part at the end of 7th year from the date of allotment. 
 
 1990
 
 - A new plant was set up at Sahibzada Ajit Singh Nagar for the
 production was commissioned.  A bulk facility to produce newer
 fluoroquinolones was also being set up at Dewas.
 
 - On 1st June, the scheme of arrangement for spinning-off the
 pharmaceutical plant at Okhla, New Delhi of the Company to Pharmax
 Corporation Ltd. was approved by the Honourable high court of Punjab
 & Haryana.
 
 - Tata Hotels Ltd., is a subsidiary of the Company with a holding of
 7,500 equity shares of Rs 10 each out of 7,600 equity shares issued.
 Since 1990, Tata Hotels Ltd. ceased to be a subsidiary of the
 company. 
 
 1991
 
 - The Company proposed to undertake backward integration into
 fermentation based products such as Penicillin and Cephalosporin-C.
 These were to be implemented at Paonta Sahib in Himachal Pradesh, a
 new complex being developed for bulk drugs.
 
 - 2,250 Pref. shares redeemed on 3.9.91.  60,75,988 bonus equity
 shares issued in prop. 2:3.
 
 1992
 
 - The Company offered 13,67,097-12.5% partly convertible debentures
 of Rs 300 each on Rights basis in the proportion of 9 debentures: 100
 equity shares held.  All were taken up.  Additional 2,05,065
 debentures were allotted to retain oversubscription.
 
 - 68,355 debentures of Rs 300 each were also issued to the employees'
 on an equitable basis.  (All were taken up).  Additional 10,253
 debentures were allotted to retain oversubscription.
 
 - Part A of Rs 200 of the face value of each debenture was to be
 compulsorily converted into 4 equity shares of Rs 10 each at a
 premium of Rs 40 per share at the end of six months from the date of
 allotment of debentures.
 
 - Part B of Rs 100 of the face value of each debenture was to be
 redeemed at par at the end of 7 years from the date of allotment of
 debentures.
 
 - RLL has three successful overseas joint ventures in Nigeria,
 Malaysia and Thailand. A joint venture recently incorporated in India
 with Eli Lilly -- a leading original research company in
 pharmaceuticals
 
 1993
 
 - During September the Company offered 24,51,719-12% fully
 convertible debentures of Rs 300 each on Rights basis in the
 proportion 15 debs: 200 equity shares held (all were taken up) (18611
 debs. were kept in abeyance).
 
 - Another 1,22,586-12% debentures were offered to the employees as an
 equitable basis (all were taken up).
 
 - Part A of Rs 125 of each debenture was to be converted into one
 equity share of Rs 10 each at a premium of Rs 15 per share on the
 date of allotment.  Accordingly 25,55,694 equity shares were allotted
 on 5.12.93.
 
 - Part B of Rs 175 of each debenture was to be converted into one
 equity share of Rs 10 each at a premium of Rs 165 per share on the
 expiry of 12 months from the date of allotment.  Accordingly
 25,55,694 equity shares were allotted on 6.12.1994.
 
 - The Company also offered 40,86,197-15% Non-Convertible debentures
 with warrants attached to it on Rights basis in the proportion 25
 NCDS  with warrants 8,200 equity shares held (all were taken up).
 
 - Another 2,04,310-15% NCDS were also offered to the employees on an
 equitable basis (all were taken up).  These would be redeemed in
 three instalments of Rs 66, Rs 67 and Rs 67 each at the end of 6th,
 7th & 8th year respectively from the date of allotment debentures.
 
 - Each NCP carries a warrant entitling the holder to apply for one
 equity share of Rs 10 each at a premium of Rs 115 per share at one or
 more instalment as may be decided by the Board during the period
 between 36th months and 60th months from the date of allotment of
 NCDS 
 at half yearly intervals.
 
 - The Company also offered 85,000-12% Full Convertible debentures
 with warrants of Rs 300 each for cash at par to Specified Entities of
 the Management Group.  Part A of debenture would be converted into one
 equity share of Rs 10 each at a premium of Rs 115 per share on the
 date 
 of allotment.  Part B of Rs 175 of each debenture was to be converted
 into one equity share of Rs 10 at a premium of Rs 165 per share.  On
 December 6th 1994, 26,40,694 equity shares of Rs 10 ech were allotted
 as per the terms of fully convertible debentures issued in December
 1993, Part B of Rs 175 each.
 
 - Each debenture has a warrant attached to the entitling the holder
 to apply for 25 equity shares of Rs 10 each for cash at a premium of
 Rs 165 per share in one or more instalment as decided by the Board,
 during the period between expiry of 12th month and 60th months from
 the date 
 of allotment of debentures.
 
 - On 5th December, 32,81,154 equity shares were issued to
 shareholders of erstwhile Crosslands Research Laboratories Ltd.  on
 its amalgamation with the Company.
 
 - It went public in Oct.'93 to part-finance manufacturing facilities
 of bulk fluoroquinolones at Dewas, MP; and dosage forms at Paonta
 Sahib, Himachal Pradesh. For easier access to the European markets 
 
 1994
 
 - The Expansion and Modernisation plant for manufacture of Ranitidine
 and Amoxycillin and a pilot plant for R&D at Toansa were commissioned.
 A new plant for manufacture of pharmaceutical dosage forms at Paonta
 Sahib was completed.
 
 - The company allotted one hundred thousand warrants without any face
 value to entities of the management group on 28th July.  Each of such
 warrants entitles the holder to subscribe to fifty equity shares of
 Rs 10 each at a premium of Rs 390 per share within a period of 18
 months
 from the date of allotment.
 
 - The Company offered 51,61,290 GDSs representing 51,61,290 equity
 share of Rs 10 each at a price of US .375 equivalent to 604.89 (at
 the rate of US .00 = 31.22) per GDS on 29th June.
 
 1995
 
 - A Global Alliance Agreement was signed with Eli Lilly and the
 Company, for marketing of pharmaceutical products in U.S.A. and other
 countries.  For the purpose of Indian joint venture, a company under
 the name Ranbaxy Lilly company was incorporated.
 
 - A join venture in U.S.A. for marketing of products from the Indian
 joint venture as also select Lilly and Ranbaxy products was proposed.
 For the purpose, a company under the name Lilly Ranbaxy
 Pharmaceuticals LLC was incorporated in the state of Indiana, U.S.A.
 
 1996
 
 - RLL bought a drug firm in Ireland in Jan.'96. In 1996, it acquired
 six leading brands from Gufic. Croslands Research Laboratories, a
 leading manufacturer of dermatological pharmaceutical formulations
 has been merged with RLL. In Oct.'98 sold off the Glat (Global
 Alliances
 and Technologies) division of Croslands to French pharma major
 Galderma.
 
 1997
 
 - The name of Ranmax Laboratories (Nigeria) Ltd., was changed to
 Ranbaxy (Nigeria) Ltd.
 
 - 1,50,000 equity shares of Rs 10 each (prem. Rs 630 per share)
 allotted on 12th June, to Ranbaxy Employees Welfare Society on
 exercise of rights attached with warrants allotted to the society. 
 2,23,958 equity shares of Rs 10 each (prem. Rs 115 per share)
 allotted on
 1.8.1997 on exercise of right attached with warrants allotted along
 with NCDs of Rs 200 each on rights basis.  6,56,423 equity shares of
 Rs 10 each (prem. Rs 115 per share) allotted on 1st February 1998 on
 exercise of right attached with warrants allotted along with NCDs of
 Rs 
 200 each on rights basis
  
 - The Company has licence arrangements with M/s. Upjohn
 International, Kalamazoo, U.S.A., M/s. Laboratoire Choay, Paris,
 France and M/s. KRKA, Ljubljana, Yugoslavia for security process and
 technical know-how for manufacturing and marketing some of their
 products in India.
 
 - Croslands Research Laboratories Limited is being merged with
 Ranbaxy Laboratories Limited. 
 
 - The company recently issued one-for-one bonus shares raising the
 equity capital to Rs.7.42 crore.  Foreign institutional investors
 (FIIs) hold over 15 per cent of the company's equity.  The two
 promoters hold around 50 per cent, the employees two per cent and the
 domestic institutions about three per cent.
 
 - The company already has a tie-up with the US-based Eli Lilly, which
 has helped it to take on the drug multinationals.
 
 - According to Gufic's managing director Jayesh Choksi, Ranbaxy
 Laboratories has acquired all the major pharmaceutical formulation
 brands of the Rs.125-crore, Mumbai-headquartered Gufic Labs. 
 
 - The annual Ranbaxy research awards were presented to five
 scientists for their outstanding contributions in medical,
 pharmaceutical and clinical sciences by Sir Gustav Nossal,
 immunologist from Australia. 
 
 - Dr Sandip Kumar Basu, Director of the National Institute of
 Immunology (NII), New Delhi, received the prize in the same category
 for his work on receptor-medicated intracellular delivery of drugs to
 macrophages, which are specialised cells important for the restoration
 
 of damaged cells, and for demonstrating the superior efficacy of
 these drugs over conventional chemotherapy. 
 
 - Ranbaxy Laboratories recently pipped Nicholas Piramal to take over
 the Mumbai based Croslands Research Laboratories sums up his
 rationale for merging his 12 year old company with the Rs. 930 crore
 Ranbaxy Industries.
 
 - RRL has been busy establishing joint ventures, strategic alliances,
 acquisitions in other countries to gain access to potential global
 markets.  RRL is one of the Indian pharma companies which was able to
 seize opportunities during the rigid FERA era of the seventies.
 
 - RRL has acquired Ohm Laboratories New Jersey, US and another
 company Rima Pharmaceuticals in the Ireland to serve the UK market
 and European Community.
 
 - RRL has resorted to a strategy of combining R&D with marketing
 probably to introduce drugs through reengineering route.  Three 50:50
 joint ventures with Eli Lilly and Company of US are planned, one to
 market products in US, another for R&D in India and yet another one
 to market Eli Lilly products in India.  The objective is to create a
 large portfolio of Eli Lilly and Ranbaxy products.
 
 - Ranbaxy Laboratories Ltd, Dabur India Ltd and Great Eastern
 Shipping Company Ltd have signed agreements with NSDL to get their
 securities admitted for dematerialisation at NSDL.
 
 - Equity shares of Ranbaxy Laboratories Ltd are accepted for
 dematerialisation at NSDL as their registrar and transfer agents,
 Karvy Consultancy Services Ltd. have already established electronic
 connectivity with NSDL.
 
 - Ranbaxy Laboratories has entered into a 50:50 joint venture with
 Specialty Laboratories Inc, of US to set up a clinical reference
 laboratory in Mumbai as well as satellite laboratories in Bangalore
 and Delhi.
 
 - These companies - Delta Drugs Private Ltd, Delta Health Care
 Private Ltd, Delta Laboratories Private Ltd, Ranbaxy Managers Welfare
 Ltd and Ranbaxy Employees Welfare Ltd hold an 11.85 per cent stake in
 the company.  In all, Ranbaxy has a share capital of 49.41 million
 shares.
 
 - The pharma major, Ranbaxy Laboratories, is all set to launch its
 first investigational new drug (IND) in the U.S. within the next 18
 months.
 
 - Shareholders of Croslands Research Laboratories Ltd (CRL) will
 receive three equity shares of Ranbaxy Laboratories Ltd (RLL) for
 every seven shares held by them.  According to company sources, the
 High Courts of Punjab, Haryana and Mumbai granted the necessary
 approvals for the scheme of amalgamation.
 
 - In 1997-98, it entered into a 50:50 joint venture with the New
 Jersey-based Schein Pharmaceuticals Inc, the generics arm of Bayer
 AG, Germany, for manufacture of Ranitidine. The company is the first
 to launch prescription products under its own label in the United
 States.
 RLL's chairman and managing director Parvinder Singh has been
 selected for Business India's businessman of the year 1998 award.
 
 1998
 
 
 - It has become India's first pharmaceutical company to launch
 prescription products under its own name and label in the U.S., the
 world's largest pharmaceutical market with an estimated 1997 sale of
 $ 101 billions.
 
 - The company has entered the U.S. ethical prescriptions market
 through Ranbaxy Pharmaceuticals Incorporated (RPI), a wholly-owned
 subsidiary of the Ranbaxy Laboratories Ltd.  The entry has been made
 with Cefaclor capsules and suspensions.
 
 - Ranbaxy Laboratories promoter Parvinder Singh has sold around 20
 lakh equity shares of the company at a price of Rs.650 per share. 
 Over a dozen foreign institutional investors (FIIs) have picked up
 these shares in a deal struck by JM Financial and Morgan Stanley.
 
 - The board of directors of pharmaceutical giant Ranbaxy Laboratories
 Ltd has recommended a bonus issue of one share for every share held,
 subject to the approval of its shareholders.
 
 - Ranbaxy Laboratories Ltd and the All-India Organisation of Chemists
 and Druggists (AIOCD) have signed a memorandum of understanding for
 various trade-related issues, including the discount structure for
 decontrolled products of Croslands, a division of Ranbaxy.
 
 - The 0-bn US insurance major Cigna has revised its memorandum of
 understanding (MoU) with Ranbaxy Laboratories for general insurance,
 including health insurance, and has entered into a fresh tripartite
 MoU which includes Infrastructure Leasing and Financial Services
 (IL&FS) 
 and Parvinder Singh, chairman, Ranbaxy, in his individual capacity.
 
 - Ranbaxy Laboratories received the National Award 1998' for
 indigenous development of technology.  The company has bagged the
 award for the third consecutive year.
 
 - Ranbaxy Laboratories Ltd has been ranked among the leading
 companies in the 1998 edition of `Review 200: Asia's leading
 companies', the annual survey conducted by Far Eastern Economic
 Review. 
 
 - On 28th Dec, 1998, the company issued bonus share in ratio of one
 new equity share for every one equity share held.
 
 1999
  
 - Pharma Majors Ranbaxy Laboratories Ltd and Glaxo Ltd announced an
 agreement for co-marketing of an advanced dosage form of the
 antibiotic cephalexin.
 
 - According to the co-marketing agreement, Ranbaxy will market the
 new dosage form as Sporidex AF, while Glaxo extends its phexin line
 with its innovated product.
 
 - Ranbaxy Laboratories Ltd and Cipla have entered into a strategic
 partnership to jointly market a select basket of drugs.
 
 - Ranbaxy Laboratories Ltd has signed an agreement with Glaxo for the
 co-marketing of an advanced dosage form of the antibiotic, Cephalexin.
 
 
 2000
 
 - The Company has filed an investigational new drug application for
 its new asthma molecule - Rbx-4638 with the Drugs Controller General
 of India (DCGI).  Ranbaxy is the first company in the country to file
 an INDA for such a novel drug compound.
 
 - Eli Lilly Ranbaxy, a 50:50 joint venture between Ranbaxy
 Laboratories and the US-based Eli Lilly & Co., has introduced
 HumaPen, a new ergonimically designed, resusable insulin delivery
 service.
 
 - Ranbaxy Laboratories Ltd (RLL) has entered into an agreement with
 Knoll Pharmaceuticals Ltd (KPL) to market the latter's leading brands
 in select overseas markets.
 
 - The Company is launching a major supply and sale offensive in the
 European markets.
 
 - The Company is the eleventh largest company in the international
 generics market.
 
 - The Company has proposed a stock option scheme for its employees
 and working directors.
 
 - Ranbaxy Pharmaceutical Inc, the US arm of pharmaceutical major
 Ranbaxy Labs, has entered into a co-marketing alliance with Purepac
 to market its generic cardiac drug Enalapril Maleate in the US
 markets.
 
 - Ranbaxy Laboratories Ltd. has launched its generic Enalapril
 Maleate tablets in the US, through its wholly-owned
 subsidiary-Ranbaxy Pharmaceuticals Inc.
 
 - Ranbaxy's late Chairman and Managing Director Parvinder Singh's
 eldest son Malvinder Mohan Singh is being moved up the ladder in the
 company as a director.
 
 - Ranbaxy Laboratories and Cipla have expanded an existing
 partnership by adding one more new drug in their co-marketing
 arrangement.
 
 - Drug major Ranbaxy Laboratories is setting up a drug discovery
 laboratory in the US.
 
 - The Company has entered into a marketing alliance with Ajanta
 Pharma to market some of its natural products in south-each Asia.
 
 - The Company has started a bioinformatics facility on its research
 and development premises at Gurgaon.
 
 - The Company is set to launch a specialised Website before the
 actual launch of the Indian version of the wonder drug, Viagra.
 
 - Ranbaxy Laboratories has launched a website www.caverta.com with
 details of its sildenafil citrate brand.
 
 - Crisil has reaffirmed the P1+ rating assigned to the Rs 130-crore
 CP programme of the company and the FAAA rating assigned to its fixed
 deposit programme.
 
 - Ranbaxy Laboratories has been awarded the US Foods and Drugs
 Administration approval for four key anti-infective products,
 representing nine formulations.
  
 - Ranbaxy Laboratories is setting up a greenfield manufacturing
 facility in Vietnam with an investment o fover  million to be
 spent over the next five years.
 
 - In Mar.'2000 it launched CLAFRINAST, this novel drug compound
 belongs to the VLA (Very Large Antigen)4 class of drug which
 represents a totally new mechanism for treatment of asthma. No such
 drug has been launched in the international market. 
 
 2001
 
 
 - Ranbaxy Laboratories is set to reap a windfall after existing the
 joint venture with the  billion US pharma major, Eli Lilly by
 selling its 50 per cent stake made at an equity investment of Rs 7.2
 crore for more than ten times at Rs 78 crore.
 
 -July 3: The US-based Eli Lilly has bought the 50 per cent stake
 owned by Ranbaxy Laboratories in the joint venture Eli Lilly Ranbaxy
 for  million.
  
 - Ranbaxy Laboratories, on August 17th, received the government's
 approval to begin selling Cifran-OD, a once-a-day form of the
 antibiotic ciprofloxacin.
 
 -Ranbaxy Laboratories and Cipla, two of the country's leading pharma
 firms, on August 27 announced an alliance to co-market the former's
 once-a-day formulation of ciprofloxacin.
 
 - The US-based Eli Lilly has bought the 50 per cent stake owned by
 Ranbaxy Laboratories in the joint venture Eli Lilly Ranbaxy for 
 million.
 
 - Ranbaxy has appointed Mr Rashmi Barbhaiya as the head of research
 and development (R&D) at Ranbaxy. 
 
 2002
 - Ranbaxy subsidiary receives tentative approval for
 commercialization of Lisinopril   Hydrochlorothiazine Tablets
 
 -  Ranbaxy Laboratories's US subsidiary has received temporary
 approval for an anti-hypertension drug, Prinizide, issued by US Food
 and Drug Administration.
 
 - Ranbaxy terminates manufacturing agreement with Eli Lilly
 
 - Ranbaxy Laboratories has recieved approval for launching the
 anti-asthma compound - Montelukast in India.
 
 - Ranbaxy obtains FDA approval to launch Ceftin
 
 - Ranbaxy obtains exclusive marketing rights for Nifedipine-XL from
 Penwest, USA
 
 - Ranbaxy Laboratories and Wockhardt on March 7th announced a
 strategic business alliance for the US, the world's largest market
 for pharmaceutical products. 
 
 - Ranbaxy introduces OTC, herbal remedies 
 
 - Ranbaxy's US subsidiary gets USFDA permission for midazolam syrup
 
 - Ranbaxy's subsidiary gets USFDA approval for acetaminophen
 
 - Ranbaxy enters biotechnology arena
 
 -Amarinder Singh resigns from Directorship of Ranbaxy Laboratories.
 
 - Ranbaxy & Schwarz Pharma sign a deal to develop new drug to treat
 benign Prostate Hyperplasia
 
 -  The Ranbaxy Laboratories has got the final approval to manufacture
 and market cefpodoxime proxetil for oral suspension from the US Food
 and Drug Administration (USFDA)
 
 - Ranbaxy obtains USFDA approval for Adderall
 
 - 4 Ranbaxy drugs included in WHO list
 
 - Ranbaxy Laboratories Ltd and Procter & Gamble Pharmaceuticals -
 Germany GmbH (P&G) today (June 26, 2002) announced the execution of
 an agreement by which Ranbaxy acquires the Brand, Veratide© in
 Germany from P&G.
 
 - Ranbaxy Lab got regulatory approval for its clinical Phase-I trials
 of its potentially anti-asthmatic entity
 
 - Ranbaxy makes a breakthrough in its R&D programme
 
 - Ranbaxy garners 90% market share of cefuroxime axetil in the US
 market
 
 - Ranbaxy gets FDA approval for Isotretinoin
 
 - Ranbaxy gets promotion and marketing rights for Verorab
 
 - FDA approved Ranbaxy Lab's new formulation
 
 - Ranbaxy changes its Asia-Pacific base to Singapore
 
 - Ranbaxy enters into marketing pact with Aventis for Hepatitis
 vaccine
 
 - Ranbaxy Labs forays domestic OTC segment
 
 - Ranbaxy gets US FDA approval for hypertension drug 
 
 - Ranbaxy Lab announces the launch of Ranbaxy Global Consumer
 Healthcare
 
 - Ranbaxy Lab members approve issue of bonus shares
 
 - Ranbaxy files highest number of PCT applications to Wipo
 
 - Ranbaxy gets US FDA permission for Lisinopril 
 
 - Ranbaxy Lab got approval by WHO for its anti-AIDs drugs
 
 -T R Mulchandani retires from Directorship of Ranbaxy.
 
 -Ranbaxy Laboratories Ltd, and Synaptic Pharmaceutical Corporation
 USA today (July 12, 2002) announced the granting of a non exclusive
 license by Synaptic to Ranbaxy. In exchange for the non-exclusive
 license; Ranbaxy will provide an up-front licensing fee, milestone
 payments and royalties to Synaptic if any drugs subject to the
 license are developed and commercialized.
 
 - Ranbaxy Laboratories Ltd has acquired a liquid manufacturing
 facility from New York based Signature Pharmaceuticals Inc., on an
 asset purchase basis through its wholly owned subsidiary Ranbaxy
 Pharmaceuticals Inc., USA.
 
 -Ranbaxy Laboratories Ltd has informed that Dr J M Khanna,
 President-R&D and Wholetime Director of the Company has retired on
 July 31, 2002.
 
 - SRL Ranbaxy, a wholly-owned venture of promoters of Ranbaxy
 Laboratories has received the prestigeous accreditation from the
 College of American Pathologists (CAP).
 
 - Ranbaxy receives approval from FDA to market Terazosin
 Hydrochloride
 
 - Ranbaxy gets US approval to manufacture and market terazosin
 
 - Ranbaxy enters into pact with Korean, Chinese biotech firms
 
 - The project of Ranbaxy Laboratories 'Crusoe,' initiated by Ranbaxy
 earlier this year, is well on track to result in a saving of Rs 100
 crore by the year '03 by way of operational efficiencies in various
 functional areas.
 
 - Ranbaxy Labs gets US approval for Augmentin Version
 
 - Ranbaxy Laboratories Ltd. (RLL) and Nippon Chemiphar Co. Ltd (NC)
 and Nihon Pharmaceutical Industry Co. Ltd. (NPI)(a subsidiary of NC)
 based in Tokyo, Japan announced  a business alliance agreement for
 US$ 50 Bn (JPY 600 billion) pharmaceuticals market in Japan. 
 
 - Ranbaxy Laboratories Ltd has informed the Exchange that Ranbaxy SA
 (Pty) a wholly owned subsidiary of Ranbaxy Laboratories Ltd and Tiger
 Brands' Healthcare division, Adcock Ingram on October 16, 2002
 announced the formation of a 50:50 Joint Venture to exclusively sell
 and distribute Ranbaxy's range of anti-retroviral products in South
 Africa
 
 - Ranbaxy Laboratories Ltd has informed the Exchange that it has
 announced an exclusive licensing agreement with K S Biomedix Ltd
 (KSB), a U K based bio-pharmaceutical company for marketing TransMID
 TM
 
 -  Ranbaxy Laboratories Ltd's fully owned subsidiary Ranbaxy
 Pharmaceuticals Inc, has secured the final approval from the US Food
 and Drug Administration (USFDA) to manufacture and market amoxicillin
 for oral suspension
 
 2003
 
 - Prof Virander S Chauhan and Dr Kanury V S Rao from the
 International Centre for Genetic Engineering, and Prof Samir K
 Brahmachari from the Institute of Genomics and Integrative Biology,
 all from Delhi, are the seven scientists who bagged Ranbaxy Research
 Awards for the year 2001.
 
 - Ranbaxy Laboratories has rolled out the GlaxoSmithkline's
 antibiotic called Augmentin, in the US market
 
 - Ranbaxy Launches next Generation Anti-Retroviral for the first time
 in India
 
 - Ranbaxy Laboratories Ltd on February 10, 2003 has announced the
 launch of a high end advanced Cephalosporin, Cefprozil, under the
 brand name Refzil O
 
 - Ranbaxy obtains USFDA approval to market Augmentin clones
 
 - Ranbaxy gets US FDA nod for Cefadroxil Oral Suspension USP
 
 - Ranbaxy receives tentative approval for manufacturing & marketing
 of Fluconazole Tablets
 
 - Ranbaxy enters into collaborative research with medicines for
 development of Anti-Malarial Drug
 
 - Ranbaxy receives USFDA approval to manufacture and Market Ofloxacin
 Tablets
 
 - Ranbaxy announces FDA approval for the manufacture and
 commercialisation of Isotretinoin Capsules
 
 - Ranbaxy Laboratories obtains approval from USFDA to manufacture
 Ganciclovir Capsules
 
 - Ranbaxy receives USFDA approval for AIDS drug
 
 - Ranbaxy Lab gets nod from FDA USA for Mfg, marketing fluconazole
 
 - Ranbaxy Latoratories is at the verge of becoming a Zero-Debt
 company. The company's secured and unsecured debt is curtailed to
 less than Rs 7 crore, this will ultimately result in substantial
 savings in the interest outgo. 
 
 - Ranbaxy Laboratories has obtained US Food and Drug Administration
 (FDA) approval to unveil a new amoxicillin antibiotic drug in US
 market.
 
 - Ranbaxy receives USFDA approval to manufacture & market Loratadine
 10 Mg tablets in the OTC market
 
 - Ranbaxy Labs and Kasturba Medical College owned by the Manipal
 Group have jointly started a clinical research centre in Manipal. 
 
 - Ranbaxy receives USFDA approval to manufacture & commercialize
 Ofloxacin tablets
 
 - Ranbaxy launches High end anti infective injectable for the first
 time in India
 
 - Ranbaxy gains USFDA approval for commercialization of Riomet
 
 -  Ranbaxy Laboratories has inked an agreement with the Andhra
 Pradesh Government for starting a research centre in the State. 
 
 - Ranbaxy gets FDA approval for diabetes drug
 
 - Company's Animal Health Division signs marketing agreement with
 Alltech Biotechnology for YeaSacc 1026 Bolus, a highly valued product
 in the dairy cattle segment
 
 - Ranbaxy Laboratories Ltd and GlaxoSmithkline plc (GSK) have entered
 into a drug discovery and clinical development collaboration covering
 a wider range of therapeutic areas.
 
 -United States Food and Drug Administration has permitted Ranbaxy
 Laboratories Ltd to manufacture and commercialise Metformin HCI oral
 solution 100 milligram per millilitre.
 
 -The company has received prestigious National Safety Awards for the
 year 2001 & 2002
 
 -Unleashed a cholesterol-reducing agent called 'Rosuvas
 (rosuvastatin)', which reduces triglycerides and raises HDL..
 
 -Ranbaxy gets FDA approval to market cephalexin
 
 -Got approval from US FDA for the manufacture and marketing of Merck
 & Co Inc's cholesterol-lowering drug  generic Zocor.
 
 -Company has received tentative approval from the office of Generic
 Drug of the US Food & Drug Administration to manufacture and market
 Metformin Hydrochloride extended-release tablets, 500 MG.
 
 -Secured USFDA approval for Simvastatin drug
 
 -Ranbaxy gets approval from US FDA  for selling its generic form of
 Bristol-Myers Squibb's cholesterol-reducing Pravachol.
 
 -Received tentative approval from the office of generic drugs of the
 US Food and Drug Administration to manufacture and market pravastatin
 sodium tablets 10mg, 20mg, 40mg, and 80 mg.
 
 -Ranbaxy Laboratories granted first USFDA Approval to manufacture and
 Market Cefaclor Tablets
 
 2004
 
 -Ranbaxy Laboratories Ltd announced that all the necessary
 formalities and consents required for the conclusion of the
 acquisition transaction of RPG (Aventis) SA have been obtained and
 that the acquisition is now complete. With this, RPG (Aventis) SA
 France has now become a wholly owned subsidiary of Ranbaxy.
 
 -Ranbaxy receives USFDA approval to commercialise Minocycline
 Hydrochloride Tablets USP
 
 -Ranbaxy Laboratories Ltd has informed that the Stock Exchange,
 Ahmedabad has advised delisting the securities of the Company
 effective January 15, 2004.
 
 - In an attempt to tap the domestic  billion herbal medicines
 market, Ranbaxy Laboratories Ltd on Jan 21 unveiled three new brands
 under the `New Age Herbals' brand. As part of its expansion in the
 over-the-counter (OTC) segment, the company has launched Olesan Oil
 for cold, Olesan cough syrup and Eat Ease, an appetite enhancer.
 Ranbaxy had forayed into the OTC market through a separate division -
 Ranbaxy Global Consumer Healthcare (RGCH) in October 2002 and is
 hoping to launch five to six products this year.
 
 -Ranbaxy Laboratories Ltd at its meeting held on January 23, 2004,
 has approved the appointment of Mr Gurcharan Das as an Additional
 Director on the board of directors of the company.
 
 -Ranbaxy Laboratories Ltd has signed a research agreement with the
 Institute of Nuclear Medical and Allied Sciences (INMAS) for
 screening and evaluation of formulations and New Drug Delivery
 Systems (NDDS) using Gamma Scintigraphy.
 
 -Ranbaxy unleashes liquid form of diabetes drug in US market
 
 -Introduces its first branded prescription medicine, Visclair tablets
 100 mcg (Mecysteine HCL) in the UK
 
 -Surpasses global sales of  billion (February 2004, MAT Basis)
 
 -Launches Forzest (Tadalafil), its most recently approved
 prescription medicine for the treatment of erectile dysfunction (ED)
 in men
 
 -Bags tentative USFDA approval to manufacture and market Quinapril
 Hydrochloride tablets used for the treatment of hypertension
 
 -Delists shares from Ludhiana Stock Exchange
 
 -The outgoing CEO and MD of Ranbaxy, Mr D S Brar, has joined the
 board of Jerry Rao-promoted Mphasis as an independent director
 
 -Ranbaxy receives Tentative approval to market Fenofibrate tablets
 
 - Ranbaxy Laboratories sets up two more wholly-owned subsidiaries in
 US  taking total number of US subsidiaries to eight from six last
 year.
 
 -Drug company Ranbaxy Laboratories Ltd said on June 22 that its
 anti-diabetic drug has got the final approval from regulatory
 authorities in the US
 
 -Ranbaxy & Atrix sign a licensing Agreement for Prostrate Cancer Drug
 in India
 
 -DS Brar exits from Ranbaxy Laboratories Ltd
 
 -Ranbaxy's anti-cancer drug Metformin is learnt to have received the
 final approval from the US Food and Drug Administration (FDA)
 
 -Indian pharma major Ranbaxy Laboratories has received final approval
 from the US FDA to manufacture and market Fluconazole tablets and oral
 suspension in varying dosages in the US.
 
 -Ranbaxy ties up with Axis-Shield to cure Rheumatoid arthritis
 
 - Ranbaxy Laboratories Ltd receives approval from U. S. Food and Drug
 Administration to manufacture and market Loratadine Syrup (Loratadine
 Oral Solution, USP), 5mg/5ml that is available to patients as an OTC
 product.
 
 - Receives tentative approval from the US Food and Drug
 Administration for generic anti-depressant, Gabapentin, in capsule
 form
 
 -Signs collaborative research agreement in the area of New Drug
 Discovery research with Avestha Gengraine Technologies Pvt Ltd
 (Avesthagen)
 
 -Ranbaxy prolongs partnership with Aventis
 
 -Ranbaxy inks pact with Ventiv to market Sotret in US
 
 -Ranbaxy launches Flotral for urological disorder amongst ageing
 males
 
 -Ranbaxy announces launch of Quinapril Tablets by Teva
 
 2005
 
 - Receivs approval from the U.S. Food and Drug Administration to
 manufacture and market Clarithromycin XL 1000 mg tablets.
 
 -Ranbaxy in alliance with Novavax to step in to biotech sector
 
 -Ranbaxy Laboratories Ltd enters into collaborative agreement with
 National Chemical Laboratories, Pune and Department of Science &
 Technology in the area of New Drug Discovery.
 
 - On May 24, 2005 launches its approved generic formulation of
 Clarithromycin immediate release (IR) tablets, 250 mg and 500 mg, in
 the US markets.
 
 -Ranbaxy's Joint Venture with Nippon Chemiphar Ltd launches Vogseal
 0.2mg & 0.3mg tablets for Diabetes
 
 -Ranbaxy sets up additional manufacturing facility in Malaysia
 
 -Ranbaxy opens third state of the art R&D facility on Gurgaon campus
 
 -Company has splits its Face value of Shares from Rs 10 to Rs 5
 
 2006
 
 -Ranbaxy Laboratories enters into a strategic alliance with Zenotech
 
 -Ranbaxy ties up with Ipca to tap US market
 
 -Ranbaxy signs licensing agreement with Swiss Company Debiopharm, for
 NCE Drug in the Gastroenterology Segment
 
 -Ranbaxy signs licensing agreement with Swiss Company Debiopharm, for
 NCE Drug in the Gastroenterology Segment.
 
 -Ranbaxy Appoints Atul Sobti as COO.
 
 -Ranbaxy Laboratories Ltd has announced that the Company has entered
 into a collaborative agreement with the Department of Science &
 Technology (DST), Government of India, New Delhi, in the area of New
 Drug Discovery Research (NDDR).
 
 -Ranbaxy granted final USFDA approval to Market Simvastatin 5, 10, 20
 & 40 MG Tablets.
 
 2007
 
 -Ranbaxy Laboratories Ltd and GlaxosmithKline (GSK) on February 06,
 2007 have signed a new multiyear R&D agreement that modifies and
 expands the terms of their strategic alliance established in 2003 to
 provide the Company expanded drug-development responsibilities and
 further financial opportunities.
 
 - Ranbaxy unveils asthma inhalation capsules.
 
 - Ranbaxy Laboratories Ltd has received final approval from the U.S.
 Food and Drug Administration (FDA) to manufacture and market
 Amlodipine Besylate Tablets, 2.5 mg (base), 5 mg (base) and 10 mg
 (base).
 
 - Ranbaxy Laboratories Ltd on August 22, 2007 has the launch of
 Roliflo OD (combination of Tamsulosin and Tolterodine) brand in the
 Indian market for the management of bladder outlet obstruction with
 concomitant overactive bladder, a chronic urological disorder. This
 is a Novel Drug Delivery System (NDDS) product which is being
 introduced for the first time in India.
 
 2008
 
 -Ranbaxy Laboratories on July 28 said it has launched the generic
 version of Omeprazole capsules, used in the treatment of acid related
 diseases in the US healthcare system.
 
 2009
 
 - Canada approves Ranbaxy's anti-hypertension drug
 
 - Daiichi launched Ranbaxy drugs in Japan
 
 -Ranbaxy subsidiary makes a deal with German health insurer
 
 - Ranbaxy launched Daiichi Sankyo's innovative antihypertensive
 drugs
 
 2010
 
 - Ranbaxy Laboratories Limited (Ranbaxy) has launched a New Chemical
 Entity (NCE), Lulifin (Luliconazole), in the Indian Dermatology
 market. This follows a strategic in-licensing agreement with Summit
 Pharmaceuticals International Corporation, Japan (SPI) allowing
 Ranbaxy, exclusive marketing rights, for India, 7'he introduction of
 this NCE, significantly strengthens Ranbaxy's presence in the
 Dermatological segment,
 
 - Ranbaxy Laboratories has entered into an agreement with US-based
 Pfenex Inc for developing biosimilars. Biosimilars are drugs which
 are manufactured with the use of biotechnology.
 
 - Ranbaxy has launched a generic version of antiplatelet agent
 Prasugrel, Prasita, in India says a report by Daiichi Sankyo and
 Ranbaxy Laboratories.
 
 - Ranbaxy arm bags Rs 605 cr order in South Africa
 
 - Ranbaxy Laboratories Limited (Ranbaxy) signed the Agreements with
 Biovcl Lifesciences Private Limited (Biovel), Bangalore, India,
 providing for the acquisition of product rights and a manufacturing
 facility, from Biovcl.
 
 - Ranbaxy and Pfenex Announce Collaboration for the Development of a
 Biosimilar Therapeutic Protein.
 
 - Ranbaxy Lab - Ranbaxy Launches Antiplatelet Agent Prasugrel in
 India
 
 -Registered Office of the Company has been shifted To A-41,
 Industrial Area Phase VIII-A, Sahibzada Ajit Singh Nagar, Mohali -
 160 071 (Punjab)
 
 2011
 
 - Ranbaxy Laboratories has entered into an in-licensing agreement
 with Gilead Sciences, Inc. for three new HIV/AIDS drugs which are
 currently in late-stage clinical development. 
 
 - Daiichi Sankyo & Ranbaxy Announce a New Social Contribution
 Initiative Encompassing India, Cameroon and Tanzania
 
 - Ranbaxy and The Government of Yaroslavl Region, Russia, sign MOU
 for cooperation in the field of Healthcare and Medical Science.
 
 - Ranbaxy Announces Launch of Atorvastatin, Generic Lipitor®, the 
 US
 
 - Ranbaxy enters into a licensing agreement with Gilead Sciences to
 manufacture and market three anti-HIV drugs in India and developing
 countries.
 
 - Ranbaxy honored with NJBIA award for excellence in New Jersey
 Business Expansion
 
 
 2012
 
 - Ranbaxy Launched Absoricatm (Isotretinoin) Capsules In The U.S.
 Healthcare Market 
 
 - Ranbaxy Delivered Strong Overall Business Performance; Improvement
 In Base Business Sales And Margins 
 
 - Ranbaxy Launched Authorized Generic Of Evoxac In The U.S.
 Healthcare Market 
 
 - Ranbaxy received Approval To Set Up Greenfield Manufacturing
 Facility In Malaysia 
 
 - Ranbaxy Launched Authorized Generic Of Pioglitazone In The U.S. 
 
 - Ranbaxy Entered Into An In-Licensing Agreement With Gilead Sciences
 To Promote Access To Reduced Cost Generic Emtricitabine And
 Emtricitabine-Containing Fixed-Dose Antiretrovirals In Developing
 Countries 
 
 - Daiichi Sankyo And Ranbaxy Launched Hybrid Business In Venezuela
 
 2013
 
 - Daiichi Sankyo Company, Limited (Daiichi Sankyo) and Ranbaxy
 Laboratories Limited (Ranbaxy) announced their intention to integrate
 their business operations in Thailand, to leverage and maximize the
 synergies of the Hybrid Business Model, which is expected to commence
 business on April 1, 2013.
Source : Dion Global Solutions Limited
Quick Links for Ranbaxy Laboratories
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.